Commentary: Predicting relapse in Crohn's disease patients in remission with biologics

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 4, 2013, Pages 497-498

  Andrews, J M ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; TUMOR NECROSIS FACTOR INHIBITOR;

COLONOSCOPY; CROHN DISEASE; DISEASE ACTIVITY; HUMAN; MAINTENANCE THERAPY; NOTE; PRIORITY JOURNAL; RELAPSE; REMISSION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; FEMALE; HUMANS; MALE;

EID: 84872702886     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12197     Document Type: Note

References (3)

1. Molnár T, Lakatos PL, Farkas K, et al,. Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy. Aliment Pharmacol Ther 2013; 37: 225-33.
2. Louis E, Mary JY, Vernier-Massouille G, et al,. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63-70.
3. Baert F, Moortgat L, Van Assche G, et al,. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138: 463-8.